GRT-C901

GRT-C901 is a cancer vaccine developed by Seattle Project. The sponsor describes its target as patient-specific neoantigens, which OnCo does not yet have a target page for. The sponsor states: A patient-specific neoantigen cancer vaccine given as the prime dose (1x10^12 viral particles, intramuscular) in a heterologous prime/boost regimen with GRT-R902, combined with checkpoint inhibition, intended to generate T-cell responses specific to each patient's tumour mutations. ClinicalTrials.gov describes the intervention as: A patient-specific neoantigen cancer vaccine administered via intramuscular (IM) injection as prime and single boost at a dose of 1x10\^12 viral particles 2 times over the course of the first year. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT05141721 (A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer), in colorectal cancer. The largest, NCT05141721, plans to enrol 700 participants with primary completion expected 2027-03. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.